Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 14.3% from a year ago
Common stock stood at $8K at the end of Q1 FY2026, up 14.3% from a year earlier and up 14.3% from the prior quarter. Over 3 fiscal years it compounded at +51.8% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +14.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 7K USD
- Year-over-year change
- +0.0%
- 3-year CAGR
- +51.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7K | +0.0% |
| FY2024 | 2024-12-31 | 7K | +250.0% |
| FY2023 | 2023-12-31 | 2K | +0.0% |
| FY2022 | 2022-12-31 | 2K | — |
Common Stock vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 common stock of $8K is the 5th highest of the 6 companies compared; the peer median is $28K.
- Its year-over-year change of +14.3% is the 2nd highest of 6, against a peer median of +0.8%.
- Common stock amounts to 0.0% of total assets for BCAX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $636K | +0.8% | +0.9% | 0.3% | |
| Mar 2026 | $91.88K | +2.4% | +79.2% | 0.2% | |
| Mar 2026 | $28K | -56.6% | -19.8% | 0.0% | |
| Mar 2026 | $18K | +28.6% | +11.5% | 0.0% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $8K | +14.3% | +51.8% | 0.0% |
| Mar 2026 | $6K | +0.0% | +6.3% | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $28K | +0.8% | +6.3% | 0.0% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.